

Sleep Apnea Therapeutic Pipeline Market Review, H2 2016

Sleep Apnea Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are



captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @ https://www.wiseguyreports.com/reports/643477-sleep-apnea-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
- The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects

- The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Get Sample Report @ https://www.wiseguyreports.com/sample-request/643477-sleep-apnea-pipeline-review-h2-2016

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ https://www.wiseguyreports.com/enquiry/643477-sleep-apnea-pipeline-review-h2-2016

Table of Content

Sleep Apnea Overview 6

Therapeutics Development 7

Pipeline Products for Sleep Apnea - Overview 7

Pipeline Products for Sleep Apnea - Comparative Analysis 8

Sleep Apnea - Therapeutics under Development by Companies 9

Sleep Apnea - Therapeutics under Investigation by Universities/Institutes 10

Sleep Apnea - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Sleep Apnea - Products under Development by Companies 14

Sleep Apnea - Products under Investigation by Universities/Institutes 15

Sleep Apnea - Companies Involved in Therapeutics Development 16

Galleon Pharmaceuticals 16

RespireRx Pharmaceuticals Inc. 17

SK Biopharmaceuticals Co., Ltd. 18

Vivus, Inc. 19

Sleep Apnea - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Combination Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 27

Drug Profiles 28

(phentermine + topiramate) ER - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CX-1739 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

dronabinol - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

GAL-475 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

GAL-475 Backups - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SKL-N05 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule for Sleep Apnea - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Sleep Apnea - Dormant Projects 46

Buy now @ https://www.wiseguyreports.com/checkout?currency=one user-USD&report id=643477 Continued...

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2016 IPD Group, Inc. All Right Reserved.